The C4A and C4B isotypic forms of human complement fragment C4b have the same intrinsic affinity for complement receptor 1 (CR1/CD35).
Several previous reports concluded that the C4b fragment of human C4A (C4Ab) binds with higher affinity to CR1 than does C4Bb. Because the isotypic residues, (1101)PCPVLD and (1101)LSPVIH in C4A and C4B, respectively, are located within the C4d region, one may have expected a direct binding contribution of C4d to the interaction with CR1. However, using surface plasmon resonance as our analytical tool, with soluble rCR1 immobilized on the biosensor chip, we failed to detect significant binding of C4d of either isotype. By contrast, binding of C4c was readily detectable. C4A and C4B, purified from plasma lacking one of the isotypes, were Cs converted to C4Ab and C4Bb. Spontaneously formed disulfide-linked dimers were separated from monomers and higher oligomers by sequential chromatographic steps. The binding sensorgrams of C4Ab and C4Bb monomers as analytes reached steady state plateaus, and these equilibrium data yielded essentially superimposable saturation curves that were well fit by a one-site binding model. Although a two-site model was required to fit the equilibrium-binding data for the dimeric forms of C4b, once again there was little difference in the K(D) values obtained for each isotype. Independent verification of our surface plasmon resonance studies came from ELISA-based inhibition experiments in which monomers of C4Ab and C4Bb were equipotent in inhibiting the binding of soluble CR1 to plate-bound C4b. Although divergent from previous reports, our results are consistent with recent C4Ad structural data that raised serious doubts about there being a conformational basis for the previously reported isotypic differences in the C4b-CR1 interaction.
Clemenza
Liliana
L
Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada.
Isenman
David E
DE
D001667:Binding, Competitive / Q000276:immunology; D003181:Complement C4 / Q000378:metabolism; D015934:Complement C4a / Q000037:antagonists & inhibitors / Q000378:metabolism*; D015935:Complement C4b / Q000037:antagonists & inhibitors / Q000378:metabolism*; D003169:Complement Inactivator Proteins / Q000378:metabolism; D019281:Dimerization; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D010446:Peptide Fragments / Q000378:metabolism; D011485:Protein Binding / Q000276:immunology; D020033:Protein Isoforms / Q000037:antagonists & inhibitors / Q000378:metabolism; D017463:Receptors, Complement 3b / Q000037:antagonists & inhibitors / Q000378:metabolism*; D011994:Recombinant Proteins / Q000378:metabolism; D012995:Solubility; D020349:Surface Plasmon Resonance
D003181:Complement C4; D003169:Complement Inactivator Proteins; D010446:Peptide Fragments; D020033:Protein Isoforms; D017463:Receptors, Complement 3b; D011994:Recombinant Proteins; C033860:complement C4c; D015934:Complement C4a; D015935:Complement C4b; C032261:complement C4d